What it's for (Indications)
- Ferric carboxymaltose (FCM) is an intravenous iron replacement product indicated for the treatment of iron deficiency anemia (IDA) in adult and pediatric patients aged 1 year and older.
- This includes patients who have intolerance to oral iron preparations or have had an unsatisfactory response to oral iron.
- It is also specifically indicated for adults with non-dialysis dependent chronic kidney disease (NDD-CKD) to manage their IDA.
- This medication is crucial for restoring iron stores and increasing hemoglobin levels in patients where oral iron is not sufficient or tolerated, thereby improving symptoms associated with anemia and enhancing overall patient well-being by addressing the underlying iron deficiency.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of ferric carboxymaltose is individualized based on the patient's iron deficiency and body weight. For adult patients, a common dosing regimen involves two doses of 750 mg administered intravenously, at least 7 days apart, for a total cumulative dose of 1500 mg. Alternatively, a single dose of 1000 mg may be administered for patients weighing 50 kg or more. For pediatric patients aged 1 year and older weighing 50 kg or more, the recommended dose is 15 mg/kg body weight, up to a maximum single dose of 750 mg, administered intravenously. For those weighing less than 50 kg, the dose is 15 mg/kg body weight, up to a maximum single dose of 500 mg. Doses are typically administered as a slow intravenous infusion over at least 15 minutes. Close monitoring of iron status, including hemoglobin, serum ferritin, and transferrin saturation, is recommended before repeat dosing to prevent iron overload and ensure optimal therapeutic response. |
Safety & Warnings
Common Side Effects
- Commonly reported side effects of ferric carboxymaltose include headache, dizziness, hypertension (elevated blood pressure), nausea, constipation, diarrhea, and reactions at the injection site such as discoloration, pain, or swelling.
- Other frequently observed adverse reactions include hypophosphatemia (low blood phosphate levels), rash, back pain, and transient flushing.
- More serious adverse effects, though less common, can include hypersensitivity reactions, ranging from pruritus and urticaria to severe anaphylaxis, characterized by hypotension, syncope, and shock.
- Patients may also experience dysgeusia (taste disturbance), transient increases in liver enzymes, or peripheral edema.
- Prompt reporting of any adverse effects to a healthcare professional is crucial for appropriate assessment and management, particularly for severe or persistent symptoms.
Serious Warnings
- Black Box Warning: While ferric carboxymaltose does not carry an FDA Black Box Warning, it is associated with significant safety concerns that necessitate careful consideration and patient monitoring. Foremost among these are **hypersensitivity reactions**, which can range from mild cutaneous symptoms to severe, life-threatening anaphylactic shock. Such reactions may occur at any time during the infusion or immediately post-infusion, requiring that patients be closely observed for at least 30 minutes following administration, with immediate access to resuscitative measures and personnel trained in managing anaphylaxis. Another critical concern is **symptomatic hypophosphatemia**. Cases of severe, symptomatic hypophosphatemia requiring clinical intervention, including intravenous phosphate supplementation, have been reported. This condition can be persistent and may necessitate monitoring of serum phosphate levels, particularly in patients at risk or those receiving repeated doses. Additionally, **transient hypertension** is a common adverse event, with significant increases in blood pressure observed in some patients. Blood pressure should be monitored, especially in those with pre-existing hypertension, to mitigate risks of cardiovascular complications. **Paravenous leakage** during infusion can lead to permanent skin discoloration (e.g., hemosiderin staining) at the injection site, highlighting the importance of proper administration technique and careful vein selection. These serious warnings underscore the need for healthcare professionals to assess patient risk factors, monitor closely during and after administration, and be prepared to manage potential complications effectively to ensure patient safety.
- Patients receiving ferric carboxymaltose should be monitored for signs of iron overload, particularly if they have underlying conditions that predispose them to it, such as hemochromatosis.
- Regular assessment of iron parameters, including serum ferritin and transferrin saturation, is recommended to guide treatment decisions and prevent excessive iron accumulation.
- Due to the potential for transient increases in blood pressure, careful monitoring of vital signs is advised during and after infusion, especially in individuals with pre-existing cardiovascular conditions or hypertension.
- Infusion should be administered slowly to minimize the risk of rapid blood pressure changes.
- Additionally, caution should be exercised in patients with active infections, as parenteral iron may exacerbate certain infections, potentially affecting clinical outcomes.
- The safety and efficacy of ferric carboxymaltose have not been established in patients undergoing hemodialysis; therefore, its use in this population requires careful clinical judgment and consideration of alternative iron therapies and dialysis-specific iron replacement strategies.
How it Works (Mechanism of Action)
Ferric carboxymaltose is an intravenous iron preparation that functions as a non-dextran iron complex. Upon administration, the iron-carbohydrate complex is endocytosed by macrophages in the reticuloendothelial system. Within these cells, the iron is released and subsequently binds to transferrin, the primary iron-transport protein, for distribution throughout the body. This iron is then utilized by erythroid precursor cells in the bone marrow for hemoglobin synthesis, crucial for oxygen transport, and by other cells for various metabolic processes requiring iron-dependent enzymes. The carbohydrate shell surrounding the iron core ensures a controlled release of iron, preventing a rapid increase in free iron, which can be toxic. This controlled delivery mechanism allows for effective replenishment of iron stores and improvement of anemic conditions with a favorable safety profile compared to older iron preparations, minimizing risks associated with high levels of unbound iron.
Commercial Brands (Alternatives)
No other brands found for this formula.